The clinical use of verapamil.
Verapamil was the first of a class of agents known as calcium entry blockers to be released for clinical use in the United States. Although only recently approved by the Food and Drug Administration (August 1981), verapamil has been used clinically in countries other than the United States for more than 15 years and has been extensively studied experimentally. Because it is now available, it is necessary for physicians to have a working understanding of its pharmacologic effects and clinical applications. Accordingly, we are reviewing reported experience with verapamil and results of its use at the Mayo Clinic.
D000284:Administration, Oral; D000328:Adult; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001682:Biological Availability; D002118:Calcium / Q000037:antagonists & inhibitors / Q000378:metabolism; D002312:Cardiomyopathy, Hypertrophic / Q000188:drug therapy; D002648:Child; D003327:Coronary Disease / Q000188:drug therapy; D004285:Dogs; D004594:Electrophysiology; D006329:Heart Conduction System / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007022:Hypotension / Q000209:etiology; D007275:Injections, Intravenous; D007700:Kinetics; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009200:Myocardial Contraction / Q000187:drug effects; D014700:Verapamil / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D014700:Verapamil; D002118:Calcium